Visus Therapeutics Announces New Scientific Data to Be Presented During the 2023 ARVO Annual Meeting
20 Apr 2023
New Non-Clinical Research Highlights the Potential Role of Alpha-Crystallin Aggregation InhibitorsAlpha-Crystallin Aggregation Inhibitors to Treat Cataract and Presbyopia
SEATTLE & IRVINE, Calif.--(BUSINESS WIRE)-- Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans, Louisiana. The presentations will highlight new research findings on the Company’s alpha-crystallin aggregation inhibitor assets. Alpha-crystallin aggregation inhibitorsAlpha-crystallin aggregation inhibitors are intended to restore elasticity and lens clarity, potentially reversing presbyopia and cataracts without the need for surgery.
“We are pleased to share these scientific findings with the ophthalmic research community at ARVO 2023,” said Rhett Schiffman, M.D., M.S., M.H.S.A., co-founder, chief medical officer and head of research and development at Visus Therapeutics. “Our non-clinical work investigates the use of alpha crystallin chaperones as aggregation inhibitors for the potential treatment of cataract, the leading cause of global blindness, and presbyopia, which affects nearly every adult over the age of 50. Exploring non-surgical therapeutic options to treat these diseases has the potential to improve the quality of life for millions of people around the world.”
The schedule of scientific presentations is as follows:
Paper Title: Intravitreal α-Crystallin Chaperone Reverses Lens Opalescence in Non-Human Primates with Spontaneous Cataracts
Date: Tuesday, April 25, 2023
Time: 9:15am – 9:30am (Central Time)
Location: 343
Presenter: James Burke, Visus Therapeutics
Poster Title: Next-Generation α-Crystallin Chaperones for the Treatment of Dysfunctional Lens Syndrome
Date: Sunday, April 23, 2023
Time: 3:45pm – 5:30pm (Central Time)
Location: Exhibit Hall
Presenter: Patrick Hughes, Visus Therapeutics
About Cataracts
A cataract is a clouding of the natural lens of the eye, making it difficult to read, drive a car, or see faces. Cataracts become common with age; more than half of all Americans aged 80 or older have cataracts or have had surgery to remove them.1
About Visus Therapeutics
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. For more information, visit and follow us on LinkedIn.
_____________________
1 Cataracts. Retrieved September 10, 2021. Johns Hopkins Medicine.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.